Is skin cIn the United States, prostate cancer is skin cancer non market leader in M Knnern with a businesswoman Tzten 192,280 new F Lle diagnosed and 27,360 cases Todesf Expected in 2009. 1 Approximately 80% of AUY922 NVP-AUY922 patients with localized disease and treatment strategies for these patients include active surveillance, radiation therapy or surgery diagnosed. Though often effective, has a definite operation with retropubic radical prostatectomy has been shown that the rate of biochemical recurrence up to 32% after 10 years. 2 For patients, the curative radiotherapy, reported a study of 1044 patients who were treated from 1977 to 1991, a 60% rate of biochemical recurrence 10 years for T1 2 patients. For those who can sentieren 3 or operate at the time of diagnosis of advanced disease or metastatic pr Androgen deprivation therapy may be effective.
The Medical Research Council completed a randomized trial of 938 patients with advanced or metastatic prostate cancer symptom assessment ADT early versus sp Th and treated reported an improvement in overall survival in patients with ADT tt. There was also the Lebensqualit t the benefits, Including. Lich reduce pathologic fracture, spinal cord compression, and ureteral obstruction 4 Unfortunately, the median duration of response to anti-androgen therapy is descr to approximately 14 to 20 months Nkt. 5 There are many second-line hormonal treatments available, but the vast majority of patients After all, are against the castration. In 2004, two Phase III studies showed docetaxel and prednisone or estramustine is castration-resistant prostate cancer with improved overall survival and quality of life Mitoxantrone based on samples t offered.
6, 7 docetaxel every 3 weeks and prednisone per day was approved by the FDA in May 2004 and is now used as the vortex Its molecules or for comparison testing of new therapeutics for metastatic CRPC. 8 deals with the median survival time for patients with docetaxel CRPC is now about 18 to 20 months. After progression on docetaxel CRPC patients have a very poor prognosis with a median survival time of approximately 6 to 10 months. 9 It is clear that more active data in this population WILL BE CORRECTED, and the orientation of the path of angiogenesis is a strategy that will be pursued actively. 1.2 Rationale for targeting angiogenic pathway, the observation that intense neovascularization is seen around the tumor growth was described in 1939 by Ide and colleagues.
10 It was sp Ter discovered that angiogenesis requires continued growth of a malignant mass and, in the absence of neovascularization is fuel, the tumor growth was associated with one end of a diameter of 2 to 3 mm. 11 Once the tumor cells are capable of their own blood supply are to recruit, k They can also develop and metastasize, a process which has been called the angiogenic switch 12th R Angiogenesis in tumor biology has been extensively studied by Judah Folkman, the group is in early to mid-1970s. 13, 14 A number of studies have suggested that it is an inductor humoral angiogenesis which was concentrated in the N Height of malignant cells. 15, 16 The subsequent Insulation is the growth factor and basic fibroblast factor 17 Gef Permeability T 18 as Vaskul Rer endothelial aroused scientific interest for further characterization of the angiogenesis .